Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
US Merck’s immuno-oncology star Keytruda (pembrolizumab) is chalking up bullish growth in Japan just as in the global market, but as such, it is nearing the range where its sales could invoke the government’s re-pricing rule, MSD Japan President Jannie…
To read the full story
Related Article
- Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
- Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
- Supply of MSD’s Hep B Vaccine Heptavax Might Be Suspended as Early as October: MHLW
April 10, 2019
- Kyorin Introduces Voluntarily Recall of Desalex
January 9, 2019
- Re-Pricing Rule for Indication Expansions Mars I/O Development: MSD Japan Chief
March 14, 2018
BUSINESS
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
- Keytruda Keeps Grip on Top Spot in July Drug Sales: Encise
August 17, 2026
- Japan Ethical Drug Sales Jump 9% in June: Crecon
August 17, 2026
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…